Compare Bank of Montreal (BMO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Gilead Sciences, Inc. — how do they compare? Bank of Montreal trades at $180.98 (market cap $125.53B), while Gilead Sciences, Inc. trades at $129.81 (market cap $161.45B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Bank of Montreal pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| BMO | GILD | |
|---|---|---|
Market Cap | $125.53B | $161.45B |
Sector | Financials | Health |
52-Week High | $180.86 | $155.80 |
52-Week Low | $110.44 | $108.22 |
Dividend Yield | 2.74% | 2.52% |
Enterprise Value | — | $175.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.
Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
